证券代码：300633 证券简称：开立医疗 公告编号：2025-005 深圳开立生物医疗科技股份有限公司 第四届董事会第七次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 2025 年 4 月 10 日，深圳开立生物医疗科技股份有限公司（以下简称"公司"） 第四届董事会第七次会议以现场和通讯表决相结合的方式在深圳市光明区光电 北路 368 号开立医疗大厦一楼会议室召开。本次会议已于 2025 年 3 月 31 日以 电话、电子邮件等方式通知全体董事。 本次会议应出席董事 7 人，实际出席董事 7 人，会议由董事长陈志强先生主 持，符合《公司章程》规定的法定人数，会议的召集、召开符合《公司法》和《公 司章程》的有关规定。 二、董事会会议审议情况 经与会董事投票表决，审议通过了如下决议： 1、审议通过《关于公司 2024 年年度报告及其摘要的议案》 公司《2024 年年度报告》及《2024 年年度报告摘要》详见巨潮资讯网。 公司第四届董事会审计委员会审议通过了该议案中的财务报告部分。 表决结果：7 票同意，0 票反对，0 票弃 ...

证券代码：300633 证券简称：开立医疗 公告编号：2025-008 深圳开立生物医疗科技股份有限公司 经天健会计师事务所（特殊普通合伙）审计，公司 2024 年度合并利润中归 属于母公司所有者的净利润为 142,397,376.09 元，2024 年度母公司度实现净利润 为 203,627,146.44 元。根据《公司章程》的规定，提取法定公积金 20,362,714.64 元，减去应付普通股股利 137,803,521.60 元，加上母公司以前年度结余未分配利 润 1,582,674,212.90 元，母公司 2024 年可供股东分配利润总计 1,628,135,123.10 元。 根据中国证监会鼓励上市公司现金分红，给予投资者稳定、合理回报的指导 意见，在符合利润分配原则，保证公司正常经营资金需求和长远发展的前提下， 根据《公司法》《公司章程》的规定，公司董事会提议拟定 2024 年度利润分配方 案如下： 公司计划以 2024 年 12 月 31 日的公司总股本 432,712,405 股扣除已回购股 份 2,890,000 股后的股份总数 429,822,405 股为基数，向全体股东每 10 股派发 ...

Financial Performance - The company reported a revenue of 1.2 billion RMB for the fiscal year 2023, representing a year-over-year growth of 15%[21]. - The company's operating revenue for 2024 is reported at ¥2,013,856,558, a decrease of 5.02% compared to ¥2,120,251,604 in 2023[26]. - Net profit attributable to shareholders for 2024 is ¥142,397,376, reflecting a significant decline of 68.67% from ¥454,437,474 in 2023[26]. - The net profit after deducting non-recurring gains and losses is ¥110,319,389.71 for 2024, down 75.07% from ¥442,470,555 in 2023[26]. - The company’s total revenue for 2024 was approximately ¥2.01 billion, a decrease of 5.02% compared to ¥2.12 billion in 2023[99]. - The revenue from ultrasound products was ¥1.18 billion, accounting for 58.75% of total revenue, with a year-on-year decline of 3.26%[99]. - The company achieved a gross margin of 63.78% in the medical device sector, down 3.93% from the previous year[100]. - International sales contributed ¥970.16 million, representing 48.17% of total revenue, with a growth of 3.27% year-on-year[99]. Research and Development - R&D and sales expenses increased year-on-year, with R&D expenses accounting for approximately 20% of current operating revenue, indicating a high level of strategic investment in new product lines[5]. - Research and development expenses increased by 10% to 120 million RMB, focusing on innovative medical technologies[21]. - The company has invested in R&D with expenditures of 328.96 million, 384.26 million, and 472.93 million yuan for the years 2022, 2023, and 2024, respectively, representing 18.66%, 18.12%, and 23.48% of total revenue[68]. - The company holds a total of 1,035 patents, including invention and utility model patents, and has been recognized as a "National High-tech Enterprise" since 2009, reflecting its strong R&D capabilities[68]. - The number of R&D personnel increased by 16.48% to 841, with a higher proportion of master's degree holders at 50.4%[109]. - The company is focusing on innovative medical devices, with several products classified as innovative medical devices under review[116]. Product Development and Launches - The company plans to rely on high-end and diversified product development strategies to continuously launch more competitive products and expand market share[4]. - New product launches include an advanced ultrasound diagnostic device expected to enhance imaging quality by 30%[21]. - The company launched high-end ultrasound machines S80 and P80 in 2024, marking a breakthrough in the high-end ultrasound field[54]. - The company has launched multiple new self-developed endoscopes, including various types of digestive and respiratory endoscopes, enhancing the user experience and aiming to elevate domestic endoscopy capabilities to handle more complex clinical scenarios[58]. - The company has introduced several new disposable medical devices intended for use with flexible endoscopes, including Disposable Needle Electrode, Disposable Coagulation Electrode, and Disposable Hot Biopsy Forceps, all classified as IIb devices[128]. Market Expansion - The company is expanding its market presence in Europe, targeting a 20% market share by the end of 2025[21]. - The company is actively expanding its minimally invasive surgical business and has introduced a team with extensive experience in surgical products and marketing[50]. - The company is expanding its market presence in Southeast Asia, targeting a 20% increase in sales in that region over the next fiscal year[196]. - The company has established a global marketing network covering nearly 170 countries and regions[82]. Strategic Initiatives - The company has initiated a strategic acquisition of a local competitor, which is projected to increase market penetration by 15%[21]. - The company has implemented several accounting policy changes effective January 1, 2024, including the adoption of new standards regarding the classification of current and non-current liabilities[27]. - The company has established a market value management plan approved on April 10, 2025, to enhance valuation[171]. - The "Quality and Return Dual Improvement" action plan has been implemented, focusing on share repurchase and high-end product launches[172]. Corporate Governance - The company has ensured compliance with corporate governance regulations, with a board of directors consisting of 7 members, including 3 independent directors[178]. - The company has established a performance evaluation and incentive mechanism for directors, supervisors, and senior management[181]. - The company operates independently from its controlling shareholder, ensuring no interference in decision-making[177]. Social Responsibility - The company’s efforts in social responsibility included providing free liver ultrasound examinations for patients with echinococcosis in western regions, contributing to the establishment of a comprehensive prevention and treatment system[95]. Financial Management - The cash inflow from investment activities in 2024 was CNY 1,015.99 million, an increase of 71.53% year-over-year, mainly due to increased redemptions of financial products[133]. - The cash outflow from investment activities surged to CNY 1,607.13 million, a significant increase of 295.70% compared to the previous year, primarily due to increased purchases of financial products[133]. - The total cash and cash equivalents decreased by CNY 202.67 million in 2024, a decline of 150.28% compared to the previous year, attributed to higher expenditures on financial products[134].

Core Viewpoint - AI is significantly transforming the productivity of the healthcare industry, with a focus on enhancing diagnostic efficiency and accuracy in medical institutions [1][2]. Group 1: AI in Healthcare - The Chinese government is promoting the "Artificial Intelligence +" initiative to better integrate digital technology with manufacturing and market advantages [2]. - At the recent China International Medical Equipment Fair (CMEF), AI was a prominent topic, with nearly 5,000 companies showcasing advanced AI medical products and services [2]. - The Vice President of KAILI Medical emphasized the importance of AI in primary healthcare, aiming to shift the market focus from hospitals to home healthcare [2]. Group 2: Market Position and Growth - KAILI Medical is a leading domestic medical device company, ranking fourth in the domestic ultrasound imaging diagnostic equipment market and first among domestic brands in digestive endoscopy [4]. - The medical device industry has experienced fluctuations due to centralized procurement and reduced hospital bidding demands, but the market is recovering due to large-scale equipment updates [4][5]. - The government has initiated policies to support equipment updates, with funding distributed based on a 9:1 principle between central and local governments [4]. Group 3: Impact of Centralized Procurement - Centralized procurement has led to a decrease in equipment sales prices; however, the increase in supply volume has positively impacted overall sales and market share for KAILI Medical [5]. - The company believes that success in centralized procurement relies on comprehensive strength and product competitiveness rather than just low prices [5]. Group 4: AI Product Development - KAILI Medical has been investing in AI technology since 2016, launching the world's first AI technology for automatic image capture in 2018, enhancing product performance [6]. - The company’s AI applications in the fields of obstetrics and gastroenterology have received positive feedback, with AI diagnostic accuracy exceeding 95% in radiology [6]. - The company is focusing on expanding AI clinical applications to assist doctors in various diagnostic scenarios [6]. Group 5: International Market Strategy - The impact of the recent "reciprocal tariffs" imposed by the U.S. is minimal for KAILI Medical, as U.S. market revenue constitutes less than 2% of total revenue [7]. - The company has established a solid overseas presence and plans to increase investments in international markets, particularly in Europe, Russia, India, and Latin America [8].

智通财经4月9日电，记者从开立医疗方面获悉，美国加征"对等关税"对公司影响不大，因为美国市场收 入在公司营业收入中的占比不到2%，且美国代理商已提前进行了适当备货。公司在海外布局多年、运 营较完善，近年来加强本地化建设，逐步在海外建立分公司。未来，公司会进一步加大海外市场投入， 重点在欧洲、俄罗斯、印度、拉美等地区拓展布局。（智通财经记者 何凡） 开立医疗回应美关税调整：公司美国市场收入占比不到2% ...

Group 1 - The 91st China International Medical Equipment Fair (CMEF) opened on April 8, showcasing Shenzhen Kaili Biomedical Technology Co., Ltd.'s (Kaili Medical) AI specialty solutions and core devices, highlighting its forward-looking layout and strong independent innovation in the smart medical field [2] - Kaili Medical launched comprehensive solutions covering ultrasound medical imaging, endoscopic diagnosis and treatment, minimally invasive surgery, and cardiovascular intervention, empowering precise smart healthcare [2] - The exhibition featured high-end ultrasound devices such as the full-body and obstetric ultrasound HETU® S80 and Dream Stream P80, equipped with the new C-Field+ intelligent platform for more accurate imaging [2] Group 2 - In the field of cardiovascular intervention, Kaili Medical's V-reader® intravascular ultrasound diagnostic system and SonoSound® catheter form an intelligent ultra-wideband intravascular imaging solution, enhancing the efficiency and usability for physicians [3] - The integration of AI and advanced technologies in the medical industry is expected to provide more opportunities for future development, with Kaili Medical focusing on the "medical devices + AI" strategy to create intelligent solutions across various medical scenarios [3]

Core Viewpoint - The 91st China International Medical Equipment Fair (CMEF) showcased cutting-edge medical technologies and devices from nearly 5,000 global enterprises, emphasizing the theme of "Innovative Technology, Leading the Future" [1] Company Highlights - KaiLi Medical, a leading domestic enterprise in ultrasound medical imaging and endoscopy, presented its innovative products and solutions under the theme "Intelligent Wave, Surge Towards New" at CMEF, highlighting its comprehensive smart diagnosis and treatment ecosystem [3] - The company introduced several high-end products across four major product lines: ultrasound medical imaging, endoscopic diagnosis and treatment, minimally invasive surgery, and cardiovascular intervention, demonstrating its strong self-research capabilities [4] - In the ultrasound medical imaging sector, KaiLi Medical showcased its ultra-high-end full-body ultrasound product, HeTu® S80, and the intelligent obstetric ultrasound product, MengXi TMP80, both featuring advanced imaging technologies for enhanced clinical solutions [4] - The new generation of the iEndo smart endoscope platform was launched, utilizing a multi-core heterogeneous hardware architecture and advanced imaging technologies to improve early cancer screening and complex lesion diagnosis [6] - In minimally invasive surgery, the company presented the "LingZhu" 4K 3D fluorescence imaging platform, which integrates various imaging modalities for precise diagnosis and treatment [7] - The cardiovascular intervention segment featured the V-reader® series intravascular ultrasound diagnostic system, designed for flexible use in sterile environments, enhancing access to quality medical resources [8] R&D and Innovation - KaiLi Medical has significantly increased its R&D investment, with expenditures reaching 338 million yuan, a year-on-year increase of 28.33%, surpassing the total R&D expenses of 2022 [10] - The company has been at the forefront of AI applications in the medical field, having launched the world's first AI technology for automatic image capture in 2018, and recently achieved a significant milestone with the first domestic AI medical device for prenatal ultrasound [10] - The introduction of the 5G + AI cloud imaging platform at CMEF allows regional hospitals to utilize AI services across various ultrasound devices, addressing interoperability issues within medical networks [11] Strategic Vision - KaiLi Medical adheres to the philosophy of "Creating More Possibilities for Life," focusing on a multi-product line strategy and continuous investment in high-end product development, aiming to fill gaps in the domestic market and enhance its competitive advantage [15]

报名：首届全球眼科大会 | 议程更新 那么，本次 医学影像展区 都将展出哪些创新产品呢？一起来看看吧！ # GE医疗 展位 ：3R13 展品 ： "英雄"磁共振结合"Sonic深度学习平台" GE医疗 是一家全球领先的医疗科技、诊断药物和数字化解决方案的创新企业，致力于通过整合解决方案和服 务提升医疗效率和精准度。公司业务遍及 160多个国家和地区 ，年营收超196亿美元，拥有全球员工51,000 名。 GE医疗的 SIGNA Hero磁共振设备通过搭载人工智能深度学习Sonic平台 ，实现了"脑心同治"理念的落地。该 设备将传统超过一小时的检查时间缩短至半小时，仅需一次造影剂注射即可完成脑心联合评估，大幅提升检查 效率和成功率。此外，SIGNA Hero还具备 高分辨斑块成像功能 ，能够评估缺血性脑卒中和心脏病风险，为不 明原因卒中患者提供全面诊断信息。 基于SIGNA Hero的脑心同治及肿瘤精准诊疗应用方案已入选《2024年高端医疗装备推广应用项目》，并由天 津医科大学总医院牵头，联合多家医院进行临床应用研究。 # 飞利浦医疗 报名：首届全球骨科大会 | 议程更新 报名：首届全球心血管大会 | 奖项申报 ...

报名：首届全球眼科大会 | 议程更新 报名：首届全球心血管大会 | 奖项申报 报名：首届全球骨科大会 | 奖项评选 合作伙伴征集：2025全球手术机器人大会 2025年4月8日至11日， 第91届中国国际医疗器械（春季）博览会（CMEF） 将在上海国家会展中心拉开帷幕。作为亚太地区规模最大的医疗科技展会，CMEF始终 是行业风向标，不仅汇聚全球创新技术，更见证着产业发展的新趋势。本届展会预计吸引 全球30多个国家和地区的近 5000家 企业，携 数万款 前沿产品集中亮相 ，以"创新科技，智领未来"为主题，共同探讨医疗科技的突破与未来。 CMEF不仅是一场产品与技术的集中展示，更是医疗行业生态的一次深度联动。从人工智能驱动的医学影像，到手术机器人赋能精准医疗，从智慧医院建设，到国 产医疗设备的崛起，CMEF2025通过高规格论坛、产业对话和技术展示，构建起全方位的交流平台，为行业发展提供新的思路与动能。 在这一医疗科技的年度盛会上，哪些企业将携最新技术亮相？哪些创新产品值得重点关注？ 思宇梳理了本届CMEF的亮点企业，一起来看它们如何在这场科技盛宴 中抢占先机！ P.S. 展位图附于文末，感兴趣的读者可按图索骥 ...

Company Overview - Shenzhen Kaili Biomedical Technology Co., Ltd. specializes in the independent research, development, production, and sales of medical diagnostic and treatment equipment, including ultrasound diagnostic devices, endoscopes, minimally invasive surgical products, and cardiovascular intervention products [2] - The company has developed HD-500 and HD-550 series high-definition endoscopes, which are widely recognized by clinical doctors and represent the leading level of domestic endoscopes [2] - Kaili Medical is one of the earliest companies in China to develop and master core technologies for color Doppler ultrasound equipment and probes, maintaining a leading position in the domestic industry [2] Market Position - As of the latest report, Kaili Medical's stock price closed at 30.4 yuan, with a rolling price-to-earnings (PE) ratio of 54.18 times, and a total market capitalization of 13.154 billion yuan [1] - The average PE ratio in the medical device industry is 46.46 times, with a median of 33.07 times, placing Kaili Medical at the 93rd position in the industry ranking [1][3] Financial Performance - For the third quarter of 2024, the company reported revenue of 1.398 billion yuan, a year-on-year decrease of 4.74%, and a net profit of 109 million yuan, down 66.01% year-on-year [3] - The gross profit margin for the company stands at 66.59% [3] Institutional Holdings - As of the third quarter of 2024, a total of 331 institutions hold shares in Kaili Medical, including 330 funds and 1 brokerage, with a total shareholding of 95.8485 million shares valued at 2.817 billion yuan [1]